Stocks Health care ARMP

NYSE · Health care

Armata Pharmaceuticals, Inc. (ARMP)

It posted a net loss of $192.2M. In fiscal 2025 capital spending exceeded operating cash flow by $26.3M. At June 30, 2026 it held $24M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.

Watch ARMP in 60 seconds

Follow ARMP

Free, no password. An email when ARMP files with the SEC.

Key facts about Armata Pharmaceuticals, Inc.

Net worth

Armata Pharmaceuticals, Inc. has a market value (market cap) of $139.4M at the latest share price, and shareholders' equity of -$231.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Cash flow

In fiscal 2025 operations used $25.8M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

Next earnings report

Armata Pharmaceuticals, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

What Armata Pharmaceuticals, Inc. does

Armata Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker ARMP.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Dividends

It paid out $80K in cash dividends.

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Armata Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 23, 2026
   Other event 8-K
2. September 14, 2026
   Investor disclosure 8-K
3. August 12, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.27 versus -$0.45.
4. August 12, 2026
   Quarterly results 8-K
5. July 20, 2026
   Investor disclosure 8-K
6. July 20, 2026
   Executive or director change 8-K
7. July 13, 2026
   Investor disclosure 8-K
8. July 13, 2026
   Employee stock plan registration S-8
9. June 24, 2026
   Executive or director change 8-K/A
10. June 23, 2026
    Other event 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 14, 2026. Insider transactions on SEC

Insider trades

What the people running Armata Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ARMP

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 207,878 shares in total, about $779.5K at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ARMP

What does Armata Pharmaceuticals, Inc. do?

Armata Pharmaceuticals, Inc. is a company in the Health care sector, listed on NYSE as ARMP. Its shares trade on NYSE under the ticker ARMP.

What is Armata Pharmaceuticals, Inc.'s net worth?

Armata Pharmaceuticals, Inc. has a market value (market cap) of $139.4M at the latest share price, and shareholders' equity of -$231.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Armata Pharmaceuticals, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $192.2M.

When did Armata Pharmaceuticals, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 23, 2026.

When is Armata Pharmaceuticals, Inc.'s next earnings report?

Armata Pharmaceuticals, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Compare ARMP with

Compare ARMP with any company

Follow ARMP

Get an email when Armata Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ARMP

Free, no password. An email when ARMP files with the SEC.

Where the numbers come from

Financial figures are the values Armata Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.